235 423

Cited 10 times in

The mortality benefit of carvedilol versus bisoprolol in patients with heart failure with reduced ejection fraction

DC Field Value Language
dc.contributor.author강석민-
dc.date.accessioned2019-10-28T01:40:49Z-
dc.date.available2019-10-28T01:40:49Z-
dc.date.issued2019-
dc.identifier.issn1226-3303-
dc.identifier.urihttps://ir.ymlib.yonsei.ac.kr/handle/22282913/171294-
dc.description.abstractBACKGROUND/AIMS: It is unknown whether different β-blockers (BBs) have variable effects on long-term survival of patients with heart failure with reduced ejection fraction (HFrEF). This study compares the effects of two BBs, carvedilol and bisoprolol, on survival in patients with HFrEF. METHODS: The Korean Acute Heart Failure (KorAHF) registry is a prospective multicenter cohort that includes 5,625 patients who were hospitalized for acute heart failure (AHF). We selected 3,016 patients with HFrEF and divided this study population into two groups: BB at discharge (n = 1,707) or no BB at discharge (n = 1,309). Among patients with BB at discharge, subgroups were formed based on carvedilol prescription (n = 831), or bisoprolol prescription (n = 553). Propensity score matching analysis was performed. RESULTS: Among patients who were prescribed a BB at discharge, 60.5% received carvedilol and 32.7% received bisoprolol. There was a significant reduction in allcause mortality in those patients with HFrEF prescribed a BB at discharge compared to those who were not (BB vs. no BB, 26.1% vs. 40.8%; hazard ratio [HR], 0.59; 95% confidence interval [CI], 0.52 to 0.67; p < 0.001). However, there was no significant difference in the rate of all-cause mortality between those receiving different types of BB (carvedilol vs. bisoprolol, 27.5% vs. 23.5%; HR, 1.21; 95% CI, 0.99 to 1.47; p = 0.07). Similar results were observed after propensity score matching analysis (508 pairs, 26.2% vs. 23.8%; HR, 1.10; 95% CI, 0.86 to 1.40; p = 0.47). CONCLUSION: In the treatment of AHF with reduced EF after hospitalization, mortality benefits of carvedilol and bisoprolol were comparable.-
dc.description.statementOfResponsibilityopen-
dc.languageEnglish-
dc.publisherKorean Association of Internal Medicine-
dc.relation.isPartOfKorean Journal of Internal Medicine-
dc.rightsCC BY-NC-ND 2.0 KR-
dc.titleThe mortality benefit of carvedilol versus bisoprolol in patients with heart failure with reduced ejection fraction-
dc.typeArticle-
dc.contributor.collegeCollege of Medicine (의과대학)-
dc.contributor.departmentDept. of Internal Medicine (내과학교실)-
dc.contributor.googleauthorKi Hong Choi-
dc.contributor.googleauthorGa Yeon Lee-
dc.contributor.googleauthorJin-Oh Choi-
dc.contributor.googleauthorEun-Seok Jeon-
dc.contributor.googleauthorHae-Young Lee-
dc.contributor.googleauthorSang Eun Lee-
dc.contributor.googleauthorJae-Joong Kim-
dc.contributor.googleauthorShung Chull Chae-
dc.contributor.googleauthorSang Hong Baek-
dc.contributor.googleauthorSeok-Min Kang-
dc.contributor.googleauthorDong-Ju Choi-
dc.contributor.googleauthorByung-Su Yoo-
dc.contributor.googleauthorKye Hun Kim-
dc.contributor.googleauthorMyeong-Chan Cho-
dc.contributor.googleauthorHyun-Young Park-
dc.contributor.googleauthorByung-Hee Oh-
dc.identifier.doi10.3904/kjim.2018.009-
dc.contributor.localIdA00037-
dc.relation.journalcodeJ02883-
dc.identifier.eissn2005-6648-
dc.identifier.pmid30317846-
dc.subject.keywordBeta-blocker-
dc.subject.keywordBisoprolol-
dc.subject.keywordCarvedilol-
dc.subject.keywordHeart failure with reduced ejection fraction-
dc.contributor.alternativeNameKang, Seok Min-
dc.contributor.affiliatedAuthor강석민-
dc.citation.volume34-
dc.citation.number5-
dc.citation.startPage1030-
dc.citation.endPage1039-
dc.identifier.bibliographicCitationKorean Journal of Internal Medicine, Vol.34(5) : 1030-1039, 2019-
dc.identifier.rimsid63832-
dc.type.rimsART-
Appears in Collections:
1. College of Medicine (의과대학) > Dept. of Internal Medicine (내과학교실) > 1. Journal Papers

qrcode

Items in DSpace are protected by copyright, with all rights reserved, unless otherwise indicated.